Ovranette 150/30 micrograms Coated Tablets

Oral contraception.

Treatment of endometriosis.

Treatment of spasmodic dysmenorrhoea and premenstrual tension.

Treatment of functional uterine bleeding (menorrhagia, metrorrhagia, metropathia haemorrhatica).

Emergency treatment of acute uterine bleeding.

Posology

Adults

How to take Ovranette

Tablets must be taken orally in the order directed on the blister package at about the same time every day, with some liquid if necessary.

Regular daily intake of tablets for 21 consecutive days is important for the preservation of contraceptive efficacy.

One tablet is to be taken daily for 21 consecutive days. Each subsequent pack is started after a 7-day tablet-free interval during which time a withdrawal bleed occurs. This usually starts on day 2-3 after the last tablet and may not have finished before the next pack is started.

How to start Ovranette

No preceding hormonal contraceptive use in the past month

Tablet-taking should start on day 1 of the woman's natural cycle (i.e. the first day of her menstrual bleeding). Additional contraception (barriers and spermicides) is not required.

Changing from another combined hormonal contraceptive (CHC)

Changing from another 21 day combined hormonal contraceptive: The first tablet of Ovranette should be taken on the first day immediately after the end of the previous oral contraceptive course. Additional precautions are not required. A withdrawal bleed should not be expected until the end of the first pack.

Changing from an Every Day (ED) 28 day combined hormonal contraceptive: The first tablet of Ovranette should be taken on the day immediately after the day on which the last active pill in the ED pack has been taken. The remaining tablets in the ED pack should be discarded. Additional precautions are not required. A withdrawal bleed should not be expected until the end of the first pack.

Changing from a progestogen-only-pill (POP)

The first tablet of Ovranette should be taken on the first day of menstruation even if the POP for that day has already been taken. The remaining tablets in the POP pack should be discarded. Additional precautions are not required.

Post-partum and post-abortum use

After pregnancy, combined hormonal contraception can be started in non-lactating women 21 days after a vaginal delivery, provided that the patient is fully ambulant and there are no puerperal complications (see section 4.4). If the pill is started later than 21 days after delivery, then alternative contraception (barriers and spermicides) should be used until oral contraception is started and for the first 7 days of pill-taking. If unprotected intercourse has taken place after 21 days post partum, then oral contraception should not be started until the first menstrual bleed after childbirth.

The use of CHCs is generally not recommended until the nursing mother has weaned her child (see section 4.6).

After miscarriage or abortion oral contraception may be started immediately.

Other indications

Endometriosis: Continuous treatment with two tablets daily.

Spasmodic dysmenorrhoea, premenstrual tension: Dosage as for oral contraception.

Functional uterine bleeding: Two tablets are taken daily on a cyclic basis as for oral contraception. In the first one or two cycles it may be necessary to give four tablets, or in exceptional cases, five.

Emergency treatment of acute uterine bleeding: Four tablets are given initially and, if necessary, 4-8 tablets daily.

Special circumstances requiring additional contraception

Management of Missed Tablets

Contraceptive reliability may be reduced if tablets are missed and particularly if the missed tablets extend the tablet-free interval. If tablets were missed in the first week of the cycle and intercourse took place in the week before the tablets were missed, the possibility of a pregnancy should be considered.

• Provided that the user is less than 12 hours late in taking any tablet, she should take it as soon as she remembers, and further tablets should be taken at the usual time.

• If she is more than 12 hours late in taking any tablet, contraceptive protection may be reduced.

• The user should take the last missed tablet as soon as she remembers, even if this means taking two tablets in one day. She then continues to take tablets at her usual time. In addition, a back-up method such as the condom should be used for the next 7 days.

• If these 7 days run beyond the last tablet in the current pack, the next pack must be started as soon as the current pack is finished; no gap should be left between packs. This prevents an extended break in tablet taking which may increase the risk of escape ovulation. The user is unlikely to have a withdrawal bleed until the end of the second pack but she may experience spotting or breakthrough bleeding on tablet taking days.

• If the user does not have a withdrawal bleed at the end of the second pack, the possibility of pregnancy must be ruled out before resuming tablet taking from the next pack.

Gastro-intestinal Upset

If vomiting or severe diarrhoea occurs within 4 hours after tablet taking, tablet absorption may be incomplete. Repeat the missed dose as soon as possible. The general advice for women using CHCs who have persistent vomiting or severe diarrhoea for more than 24 hours is to follow the instructions for missed pills.

How to delay a period

To delay a period the woman should continue with another pack of Ovranette without a tablet-free interval. The extension can be carried on for as long as wished until the end of the second pack. During the extension the woman may experience breakthrough-bleeding or spotting.

Regular intake of Ovranette is then resumed after the usual 7 day tablet-free interval.

Elderly

Not applicable.

Paediatric population

Not applicable.

Method of administration

For oral administration.

Ovranette should not be used in the presence of any of the conditions listed below. Should any of the conditions appear for the first time during Ovranette use, the product should be stopped immediately.

• Breastfeeding: <6 weeks postpartum

• History of confirmed venous thromboembolism (VTE). Known risk factors for VTE.

• Arterial thrombotic disorders (Cerebrovascular accident or coronary artery disease) or a history of these conditions, or prodromal conditions (e.g. angina pectoris and transient ischaemic attack)

• Smoking in women aged ≥ 35 years who smoke ≥ 15 cigarettes per day

• Severe or uncontrolled hypertension

• Known thrombogenic mutations, thrombogenic valvulopathies or congenital heart disease

• History of migraine with focal neurological symptoms

• Diabetes mellitus with vascular involvement

• Systemic Lupus Erythematosus (SLE) with positive (or unknown) antiphospholipid antibodies

• The presence of a severe or multiple risk factor(s) for venous or arterial thrombosis may also constitute a contraindication (see section 4.4)

• Acute or severe chronic liver diseases, current or previous, as long as liver function values have not returned to normal

• Presence or history of liver tumours (benign or malignant)

• Known or suspected carcinoma of the breast or other known or suspected estrogen-dependent neoplasia

• Undiagnosed vaginal bleeding

• Hypersensitivity to the active substances or to any of the excipients listed in section 6.1.

Ovranette is contraindicated for concomitant use with medicinal products containing ombitasvir/paritaprevir/ritonavir, dasabuvir, glecaprevir/pibrentasvir or sofosbuvir/velpatasvir/voxilaprevir (see section 4.5).

Assessment of women prior to starting hormonal contraceptives (and at regular intervals thereafter) should include a personal and family medical history of each woman. Physical examination should be guided by this and by the Contraindications (section 4.3) and Special warnings and precautions for use (section 4.4) for this product. The frequency and nature of these assessments should be based upon relevant guidelines and should be adapted to the individual woman, but should include measurement of blood pressure and, if judged appropriate by the clinician, breast, abdominal and pelvic examination, including cervical cytology.

Before starting treatment, pregnancy must be excluded.

In cases of undiagnosed abnormal genital bleeding, adequate diagnostic measures are indicated.

Warnings

Patients should be counselled that this product does not protect against HIV infection (AIDS) and other sexually transmitted diseases.

The suitability of a combined hormonal contraceptive should be judged according to the severity of such conditions in the individual case, and should be discussed with the patient before she decides to take it.

Minimising exposure to estrogens and progestogens is in keeping with good principles of therapeutics. For any particular estrogen/progestogen combination, the dosage regimen prescribed should be one that contains the least amount of estrogen and progestogen that is compatible with a low failure rate and the needs of the patient.

Conditions requiring supervision:

Ovranette can be used in women with a condition that falls into WHO category 3, but as the theoretical or proven risks usually outweigh the advantages of using the CHC, the decision to prescribe the CHC must be made using clinical judgment and in consultation with the woman. If any of these conditions appear for the first time during Ovranette use, consideration should be given to stopping CHC use.

• Breastfeeding - ≥ 6 weeks to <6 months postpartum (primarily breastfeeding)

• Postpartum (in non-breastfeeding women) - <21 days

• Smoking – aged ≥ 35 years and smoking <15 cigarettes/day

• Cardiovascular Disease – Multiple risk factors for arterial cardiovascular disease (such as older age, smoking, diabetes and hypertension)

• Hypertension – adequately controlled hypertension: elevated blood pressure levels systolic 140-159 mmHg or diastolic 90-94 mmHg

• Known Hyperlipidaemias

• Migraine Headaches – past history of migraine with aura; new onset migraine (see below)

• Breast Cancer – past and no evidence of current disease for 5 years

• Diabetes - with mild vascular disease or mild nephropathy, retinopathy, or neuropathy

• Gallbladder Disease – current or medically treated symptomatic gallbladder disease

• History of Cholestasis – past CHC-related

• Viral Hepatitis – acute or flare.

Reasons for stopping Ovranette immediately:

• Occurrence of migraine in patients who have never previously suffered from it. Exacerbation of pre-existing migraine. Any unusually frequent or unusually severe headaches.

• Any kind of acute disturbance of vision

• Suspicion of thrombosis or infarction including symptoms such as unusual pains in or swelling of the legs, stabbing pains on breathing, persistent cough or coughing blood, pain or tightness in the chest

• Significant rise in blood-pressure

• Jaundice

• Clear exacerbation of conditions known to be capable of deteriorating during hormonal contraception or pregnancy (see “ Other” in section 4.4).

If hormonal contraception is stopped for any reason and pregnancy is not desired, it is recommended that alternative non-hormonal methods of contraception (such as barriers or spermicides) are used to ensure contraceptive protection is maintained.

Circulatory Disorders

Use of CHCs is associated with an increased risk of venous and arterial thrombotic and thromboembolic events. The presence of one serious or multiple risk factors, depending on type and severity, for venous or arterial disease, may constitute an unacceptable level of risk (see section 4.3).

Risk of venous thromboembolism (VTE)

The use of any CHC carries an increased risk of venous thromboembolism (VTE) events compared with no use. Products that contain levonorgestrel (including Ovranette), norgestimate or norethisterone are associated with the lowest risk of VTE. The decision to use Ovranette should be taken after a discussion with the woman to ensure she understands the risk of VTE with Ovranette, how her current risk factors influence this risk, and that her VTE risk is highest in the first ever year of use. There is also some evidence that the risk is increased when a CHC is re-started after a break in use of 4 weeks or more.

In women who do not use a CHC and are not pregnant about 2 out of 10,000 will develop a VTE over the period of one year. However, in any individual woman the risk may be far higher, depending on her underlying risk factors (see below).

It is estimated that out of 10,000 women who use a low dose CHC that contains levonorgestrel, about 6¹ will develop a VTE in one year.

This number of VTEs per year is fewer than the number expected in women during pregnancy or in the postpartum period.

VTE may be fatal in 1-2% of cases.

Number of VTE events per 10,000 women in one year

The level of all these risks of VTE increases with age and is likely to be further increased in women with other known risk factors for VTE. Caution must be exercised when prescribing CHCs for such women.

The risk for venous thromboembolic complications in CHCs users increases with:

• A personal or family history of VTE; certain inherited and acquired thrombophilias (see below)

• Obesity (body mass index of 30 kg/m² or over)

• Recent delivery or second-trimester abortion

• Prolonged immobilisation, major surgery or trauma with increased risk of thrombosis (see below)

• Increasing age

• Systemic lupus erythematosus (SLE).

There is no consensus about the possible role of varicose veins and superficial thrombophlebitis in VTE.

The relative risk of post-operative thromboembolic complications has been reported to be increased two- or four-fold with the use of CHCs. If feasible, CHCs should be discontinued for at least 6 weeks prior to and for two weeks after elective surgery with increased risk of thrombosis, or during prolonged immobilization.

Symptoms of VTE events can include

• Severe pain in the calf of one leg; swelling of the lower leg

• Sudden breathlessness, chest pain

• Sudden partial or complete loss of vision.

Arterial Thrombosis and Thromboembolism

Epidemiological studies have suggested an association between the use of CHCs and an increased risk for arterial thrombotic and thromboembolic events - primarily myocardial infarction and cerebrovascular events (transient ischaemic attack or stroke).

Cigarette smoking increases the risk of serious cardiovascular adverse reactions from CHC use. This risk increases with age and with the extent of smoking, and is quite marked in women over 35 years of age. Women who use CHCs should be strongly advised not to smoke.

The risk of arterial thrombotic and thromboembolic events is further increased in women with underlying risk factors (see below) and caution must be exercised when prescribing CHCs for such women.

Examples of risk factors for arterial thrombotic and thromboembolic events include:

• Increasing age

• Smoking, especially over the age of 35

• Family history of arterial thromboembolic events; certain inherited and acquired thrombophilias (see below)

• Hypertension

• Dyslipoproteinaemias

• Thrombogenic valvular heart disease, atrial fibrillation

• Obesity (body mass index of 30 kg/m²)

• Diabetes

• Systemic Lupus Erythematosus (SLE)

• Migraine.

The onset or exacerbation of migraine or development of headache with a new pattern that is recurrent, persistent or severe requires discontinuation of CHCs and evaluation of the cause. CHC users with migraine (particularly migraine with aura) may be at increased risk of stroke (see section 4.3).

Symptoms of arterial thrombotic/thromboembolic events or of a cerebrovascular accident can include:

• Sudden severe pain in the chest, whether or not it radiates to the left arm

• Sudden onset of coughing; for no apparent reason

• Any unusual, severe, prolonged headache

• Sudden partial or complete loss of vision or diplopia

• Slurred speech or aphasia

• Vertigo

• Collapse with or without focal seizure

• Weakness or very marked numbness suddenly affecting one side or one part of the body, motor disturbances.

Other factors affecting circulatory events

Other medical conditions which have been associated with adverse vascular events include chronic inflammatory bowel disease (Crohn's disease or ulcerative colitis) and sickle cell disease.

Biochemical factors that may be indicative of hereditary or acquired predisposition for venous or arterial thrombosis include Activated Protein C (APC) resistance, hyperhomocysteinemia, antithrombin-III deficiency, protein C deficiency, protein S deficiency, antiphospholipid antibodies (anticardiolipin antibodies, lupus anticoagulant).

Tumours

Numerous epidemiological studies have been reported on the risks of ovarian and endometrial cancer, in women using combined hormonal contraceptives. The evidence is clear that high dose combined hormonal contraceptives offer substantial protection against both ovarian and endometrial cancer. However, it is not clear whether low dose CHCs confer protective effects to the same level.

Breast Cancer

A meta-analysis from 54 epidemiological studies reported that there is a slightly increased relative risk (RR = 1.24) of having breast cancer diagnosed in women who are currently using combined hormonal contraceptives (CHCs). The observed pattern of increased risk may be due to an earlier diagnosis of breast cancer in CHC users, the biological effects of CHCs or a combination of both. The additional breast cancers diagnosed in current users of CHCs or in women who have used CHCs in the last ten years are more likely to be localised to the breast than those in women who never used CHCs.

Breast cancer is rare among women under 40 years of age whether or not they take CHCs. Whilst this background risk increases with age, the excess number of breast cancer diagnoses in current and recent CHC users is small in relation to the overall risk of breast cancer (see bar chart).

The most important risk factor for breast cancer in CHC users is the age women discontinue the CHC; the older the age at stopping, the more breast cancers are diagnosed. Duration of use is less important and the excess risk gradually disappears during the course of the 10 years after stopping CHC use such that by 10 years there appears to be no excess.

The possible increase in risk of breast cancer should be discussed with the user and weighed against the benefits of CHCs taking into account the evidence that they offer substantial protection against the risk of developing certain other cancers (e.g. ovarian and endometrial cancer).

Cervical Cancer

The most important risk factor for cervical cancer is persistent HPV infection. Some epidemiological studies have indicated that long-term use of CHCs may further contribute to this increased risk but there continues to be controversy about the extent to which this finding is attributable to confounding effects, e.g. cervical screening and sexual behaviour including use of barrier contraceptives.

Hepatic Neoplasia/Liver Disease

Benign and malignant liver tumours have been reported very rarely in users of CHCs. The risk appears to increase with duration of CHC use. In isolated cases these tumours have led to life threatening intra-abdominal haemorrhage. Hepatic tumour should be considered in women presenting with severe upper abdominal pain or liver enlargement (see section 4.3).

Other conditions:

Hypertension

Hypertension increases the risk of stroke and MI (see section 4.4). Although small increases in blood pressure have been reported in many women taking CHCs, clinically relevant increases are rare.

If sustained, significant increase in blood pressure occurs, CHCs should be discontinued. CHC use is contraindicated in women with uncontrolled hypertension (see section 4.3). Where considered appropriate, CHC use may be resumed if normotensive values can be achieved with antihypertensive therapy.

Gallbladder Disease

CHCs may increase the risk of gallbladder disease and may worsen existing disease. For women with symptomatic gallbladder disease, consideration should be given to whether the benefits of CHCs outweigh the risks.

Diabetes

Insulin-dependent diabetics without vascular disease can use CHCs. However, it should be remembered that all diabetics and patients with impaired glucose tolerance are at an increased risk of arterial disease and this should be considered when prescribing CHCs. Diabetics with existing vascular disease are contraindicated from using CHCs (see section 4.3).

Known hyperlipidaemias

Women with hypertriglyceridemia, or a family history thereof, may be at an increased risk of pancreatitis when using CHCs.

Women who are being treated for hyperlipidaemias are at an increased risk for arterial disease and should be followed closely if they elect to use CHCs. However, routine screening of women on CHCs is not appropriate.

Conditions which deteriorate in pregnancy or during previous CHC use

The following conditions have been reported to occur or deteriorate with both pregnancy and CHC use. Such patients who use CHCs should be carefully monitored. Consideration should be given to stopping Ovranette if any of the following occur during use:

• Raised blood pressure

• Jaundice and/or pruritus related to cholestasis

• Herpes gestationis

• Chloasma

• Systemic lupus erythematosus (SLE)

• Severe headaches

• Exogenous estrogens may induce or exacerbate symptoms of hereditary and acquired angioedema

• Mood changes, including depressed mood

• Or any other condition an individual woman has experienced worsening of during pregnancy or previous use of CHCs.

Bleeding Irregularities

Irregular bleeding may occur especially during the first 3 months of CHC use. If bleeding irregularities persist or occur after previously regular cycles, then non-hormonal causes should be considered and adequate diagnostic measures are indicated to exclude malignancy or pregnancy.

Some women may encounter post-pill amenorrhea (possibly with anovulation) or oligomenorrhea, especially when such a condition was pre-existent.

Ovranette contains sucrose and lactose

This product contains lactose and sucrose. Patients with rare hereditary problems of galactose intolerance, fructose intolerance, the Lapp lactase deficiency, glucose-galactose malabsorption or sucrase-isomaltase insufficiency should not take Ovranette.

Depression

Depressed mood and depression are well-known undesirable effects of hormonal contraceptive use (see section 4.8). Depression can be serious and is a well-known risk factor for suicidal behaviour and suicide. Women should be advised to contact their physician in case of mood changes and depressive symptoms, including shortly after initiating the treatment.

¹ Mid-point of range of 5-7 per 10,000 WY, based on a relative risk for CHCs containing levonorgestrel versus non-use of approximately 2.3 to 3.6.

Interactions between ethinylestradiol (EE) and/or levonorgestrel (LNG) and other substances may lead to decreased or increased serum EE and/or LNG concentrations. The prescribing information of concomitant medications should be consulted to identify potential interactions.

Other drug interactions:

Hormonal contraceptives may interfere with the metabolism of certain other drugs.

Increased plasma concentrations of ciclosporin and theophylline have been reported with concomitant administration of OCs. CHCs have been shown to induce metabolism of lamotrigine resulting in sub-therapeutic plasma concentrations of lamotrigine.

Laboratory tests

The use of contraceptive steroids may influence the results of certain laboratory tests, including biochemical parameters of liver, thyroid, adrenal and renal function, plasma levels of (carrier) proteins (e.g. corticosteroid binding globulin and lipid/lipoprotein fractions), parameters of carbohydrate metabolism and parameters of coagulation and fibrinolysis. Changes generally remain within the normal laboratory range.

Pharmacodynamic interactions

During clinical trials with patients treated for hepatitis C virus infections (HCV) with medicinal products containing ombitasvir/paritaprevir/ritonavir, dasabuvir with or without ribavirin, transaminase (ALT) elevations higher than 5 times the upper limit of normal (ULN) occurred significantly more frequently in women using ethinylestradiol-containing medications such as CHCs. Additionally, also in patients treated with glecaprevir/pibrentasvir or sofosbuvir/velpatasvir/voxilaprevir, ALT elevations were observed in women using ethinylestradiol-containing medications such as CHCs (see section 4.3).

Therefore, Ovranette users must switch to an alternative method of contraception (e.g., progestogen-only contraception or non-hormonal methods) prior to starting therapy with these combination drug regimens. Ovranette can be restarted 2 weeks following completion of treatment with these combination drug regimens.

Pregnancy

Ovranette is not indicated during pregnancy.

In cases of suspected pregnancy, pregnancy should be confirmed promptly before initiating or discontinuing treatment.

Extensive epidemiological studies have revealed neither an increased risk of birth defects in children born to women who used CHCs prior to pregnancy, nor a teratogenic effect at unintentional intake of contraceptive pills in early pregnancy.

Breast-feeding

Lactation may be influenced by contraceptive pills as they may reduce the amount of breast milk and change its composition. Thus, the use of combined hormonal contraceptives should generally not be recommended until the nursing mother has weaned her child off breast milk. Small amounts of the contraceptive steroids and/or their metabolites may be excreted in breast milk. These amounts may affect the child.

Ovranette has no or negligible influence on the ability to drive and use machines.

Use of CHCs has been associated with increased risk of the following:

• Arterial and venous thrombotic and thromboembolic events, including myocardial infarction, stroke, transient ischemic attack, retinal vein thrombosis, venous thrombosis and pulmonary embolism*

• Cervical intraepithelial neoplasia and cervical cancer*

• Breast cancer diagnosis*

• Benign hepatic tumours (e.g. focal nodular hyperplasia, hepatic adenoma)*

• Conditions reported to deteriorate with pregnancy or previous CHC use include: Crohn's disease, ulcerative colitis, porphyria, systemic lupus erythematosus, herpes gestationis, exacerbation of chorea, cholestatic jaundice

Within the organ system classes, adverse reactions are listed under the headings of frequency (number of patients expected to experience the reaction), using the following categories:

* Please refer to section 4.4 for more information.

Reporting of suspected adverse reactions

Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the Yellow Card Scheme at www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store.

Symptoms of hormonal contraceptive overdosage in adults and children may include nausea, vomiting, breast tenderness, dizziness, abdominal pain, drowsiness/fatigue; vaginal bleeding may occur in females.

There is no specific antidote and further treatment of overdose, if necessary, is directed to the symptoms.

Pharmacotherapeutic group: Progestogens and estrogens, fixed combinations. ATC code: G03FA11.

Ethinylestradiol is a synthetic oestrogen which has actions and uses similar to those of oestradiol, but is much more potent.

Norgestrel is a progestational agent with actions similar to those of progesterone. It is more potent as an inhibitor of ovulation than norethisterone and has androgenic activity.

Norgestrel inhibits ovulation by suppressing gonadotrophins, leading to the contraceptive effect.

Ethinylestradiol is absorbed by the gastro-intestinal tract. It is only slowly metabolised and excreted in the urine.

Norgestrel is absorbed from the gastrointestinal tract. Metabolites are excreted in the urine and faeces as glucuronide and sulphate conjugates.

Nothing of relevance to the prescriber.

Core:

Lactose monohydrate

Maize starch

Povidone 25

Magnesium stearate

Talc

Purified water

Coating:

Sucrose

Polyethylene glycol 6000

Calcium carbonate

Talc

Povidone 90

Purified water

White wax

Wax carnauba

Not applicable.

3 years.

Do not store above 25° C.

Aluminium foil and PVC blister strip of 21 tablets.

Each blister strip is packaged in an aluminium foil pouch together with a silica gel desiccant sachet.

Cartons containing 1, 3 and 50 blisters.

Not all pack sizes may be marketed.

No special requirements for disposal.